<DOC>
	<DOCNO>NCT00864370</DOCNO>
	<brief_summary>Very little known impact pregnancy postpartum period BPD . As result , investigator little evidence base treatment guideline . The main goal study help fill gap find risk factor BPD relapse pregnancy postpartum period . The risk factor investigator study include : 1. severity illness past 2. type severity recent past stressor 3. treatment receive pregnancy postpartum period . Other goal study : 1. see effect , , illness medicine take pregnancy baby 's well-being delivery 2. see pregnancy alters way body clear medicine take BPD 3. see much medicine baby expose pregnancy breast-feeding . The investigator believe information gather study lead new treatment guideline BPD pregnancy postpartum period improve outcome pregnant woman BPD baby .</brief_summary>
	<brief_title>Bipolar Disorder ( BPD ) Pregnancy : Predictors Morbidity</brief_title>
	<detailed_description>Despite significant morbidity bipolar disorder ( BPD ) high prevalence childbearing year , remarkably little known impact female reproductive life cycle BPD . Clinicians lack evidence-based guideline perinatal management BPD . The proposal address understudied area considerable public health implication estimate 100,000 woman BPD conceive year US . The broad goal project delineate clinical , psychosocial , particular , pharmacologic predictor BPD recurrence pregnancy . Preliminary finding suggest inadequate treatment particularly robust predictor prenatal BPD recurrence . Consequently , specific emphasis place investigate recurrence risk associate suboptimal pharmacotherapy occur result medication discontinuation decline drug concentration secondary increase prenatal clearance . A prospective cohort design monthly assessment implement collaborative investigation two leading perinatal psychiatry academic center US specific expertise mood disorder research pregnancy . The specific aim 1 ) quantify risk syndromal subsyndromal prenatal BPD illness associate suboptimal pharmacotherapy control severity previous course illness recent psychosocial stressor , 2 ) examine association maternal prenatal BPD morbidity psychotropic exposure infant outcome delivery thereby fill current void round requisite facet clinical risk/benefit assessment , 3 ) conduct pharmacokinetic ( PK ) model effort delineate pregnancy-associated change drug clearance provide initial reliable estimate fetal drug exposure . Study result represent incremental advance : 1 ) elucidate risk factor BPD morbidity pregnancy ; 2 ) contributes clinically relevant data establish therapeutic guideline BPD pregnancy ; 3 ) serve basis preventive strategy aim optimize maternal infant outcome . Furthermore , novel PK data expand understanding prenatal drug metabolism , project establish cohort child woman BPD detail prospective prenatal history .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Medically healthy adult woman ( age 1845 ) fulfil DSMIV criterion BPD subtype â‰¥ 16 week gestation date last menstrual period ( LMP ) Able give inform consent comply study procedure Actively suicidal homicidal Active substance use disorder within 6 month prior enrollment Positive urine drug screen Hematocrit &lt; 30</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Psychiatry</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>